Ventyx Biosciences Inc (VTYX)

$5.81 -0.79 (-11.97%)
Market Cap 414.31M
Revenue (ttm) 0.00
Net Income (ttm) -135.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 12,475,399
Avg Vol 3,994,132
Day's Range N/A - N/A
Shares Out 71.31M
Stochastic %K 54%
Beta 1.01
Analysts Strong Sell
Price Target $11.50

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 593 4832
Address:
12790 El Camino Real, Suite 200, San Diego, United States
MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 2:38 AM
Enter: $VTYX Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.60 Sell Price: $0.98 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
_trendchaserz
_trendchaserz Oct. 26 at 1:43 AM
Market’s been tricky, but @Invinc1ble been adapting quick. Worth a follow👌 $NVFY $VTYX $SRFM $LASE Queues
0 · Reply
Patienceworks983
Patienceworks983 Oct. 25 at 7:49 PM
$CIFR $HIVE $LAES $SCNX $VTYX no diversity needed. thank you though. 🙏
1 · Reply
josh77
josh77 Oct. 25 at 7:42 PM
$ICU Strategic Partnership Scenario Trigger: Collaboration with a major medtech or dialysis provider Catalyst: Licensing deal or co-commercialization agreement Impact: Validates technology Provides non-dilutive funding Expands distribution and hospital access Stock Price Potential: $2.X–$4.X range, depending on deal terms $WGRX $VTYX $VTGN $VKTX
0 · Reply
BinaryLogic
BinaryLogic Oct. 25 at 7:28 PM
$VTYX $SCNX $CIFR $LAES WKEY $HIVE [Diversification] The strategy has not changed for me. Make sure that you diversify your positions by Company and sector so that you can capitalize on opportunities where they present themselves. Last week VTYX soared 100%, SCNX 400%, LAES/WKEY started a possible breakout, Miners recorded well on a technical correction along with AI/HPC infrastructure and high beta more broadly did well to close the week.
1 · Reply
fabiolus
fabiolus Oct. 25 at 6:16 PM
$VTYX The cardiometabolic Phase 2 readout for VTX3232 is now public and positive. The science on this asset is largely de-risked. The remaining clinical update this year is the recurrent pericarditis readout for VTX2735. If successful, that would establish a second validated program in a commercially meaningful cardiovascular indication. The key shift now is on the business side: Sanofi holds a Right of First Negotiation on VTX3232 (source: SEC Form 10-Q / 8-K). With the latest data now available, that negotiation window has effectively opened , which means Sanofi is reviewing the full dataset right now, ahead of the rest of the market. Market cap is still around $600M. Any visibility on partnering or commercial strategy can materially re-rate valuation from here. This is no longer a biology story. It’s now a strategic one.
0 · Reply
userD
userD Oct. 25 at 5:52 PM
$VTYX $VIGL $TRML
0 · Reply
buttermeupalready
buttermeupalready Oct. 25 at 4:36 PM
$VTYX this thing is a gem and going to be one of the shining stars for biotech in 25
0 · Reply
Longroader
Longroader Oct. 25 at 3:36 PM
$VTYX Sanofi bought $VIGL for $470M + $100M CVR for a single P1 Alzheimers'. And $TRML was bought out for $1.4B. ASCVD. Ignore the noise. Stay focused.
0 · Reply
agamemnus
agamemnus Oct. 25 at 1:29 PM
$VTYX clinical efficacy data in recurrent pericarditis likely coming mid-November. That's a pretty rare condition.. 10-20,000 patients in the US. Likely qualifies for orphan drug status. Current best treatment is through IV, branded Arcalyst. $200K a year. Almost $300M in sales in 2024. Because it's such a rare condition, recurrent pericarditis can get approved relatively quickly. Importantly, there's read-through from VTX-3232 to VTX-2735 because both are NLRP3 inhibitors. More tidbits will be coming on Parkinson's front as well. They're planning a phase 2 trial but I think they will likely simply partner it and ... this can solve the cash runway for the entire company.
1 · Reply
Latest News on VTYX
Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Oct 24, 2025, 2:17 AM EDT - 2 days ago

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Oct 22, 2025, 4:02 PM EDT - 3 days ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 27, 2025, 7:02 AM EDT - 2 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Jun 17, 2025, 7:00 AM EDT - 4 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 5 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025, 4:01 PM EDT - 6 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 27, 2025, 4:05 PM EST - 8 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 18, 2025, 8:00 AM EST - 8 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 9 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Jan 14, 2025, 8:00 AM EST - 10 months ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Nov 4, 2024, 10:32 AM EST - 1 year ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 13, 2024, 7:13 AM EDT - 1 year ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 12, 2024, 4:04 PM EDT - 1 year ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 3:37 PM EDT - 1 year ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 11, 2024, 6:41 AM EDT - 1 year ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 8, 2024, 5:24 AM EDT - 1 year ago

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Jun 5, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

May 16, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:58 PM EDT - 1 year ago

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 30, 2024, 8:00 AM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 28, 2024, 7:00 PM EDT - 1 year ago

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Apr 28, 2024, 1:00 PM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 2:38 AM
Enter: $VTYX Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.60 Sell Price: $0.98 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
_trendchaserz
_trendchaserz Oct. 26 at 1:43 AM
Market’s been tricky, but @Invinc1ble been adapting quick. Worth a follow👌 $NVFY $VTYX $SRFM $LASE Queues
0 · Reply
Patienceworks983
Patienceworks983 Oct. 25 at 7:49 PM
$CIFR $HIVE $LAES $SCNX $VTYX no diversity needed. thank you though. 🙏
1 · Reply
josh77
josh77 Oct. 25 at 7:42 PM
$ICU Strategic Partnership Scenario Trigger: Collaboration with a major medtech or dialysis provider Catalyst: Licensing deal or co-commercialization agreement Impact: Validates technology Provides non-dilutive funding Expands distribution and hospital access Stock Price Potential: $2.X–$4.X range, depending on deal terms $WGRX $VTYX $VTGN $VKTX
0 · Reply
BinaryLogic
BinaryLogic Oct. 25 at 7:28 PM
$VTYX $SCNX $CIFR $LAES WKEY $HIVE [Diversification] The strategy has not changed for me. Make sure that you diversify your positions by Company and sector so that you can capitalize on opportunities where they present themselves. Last week VTYX soared 100%, SCNX 400%, LAES/WKEY started a possible breakout, Miners recorded well on a technical correction along with AI/HPC infrastructure and high beta more broadly did well to close the week.
1 · Reply
fabiolus
fabiolus Oct. 25 at 6:16 PM
$VTYX The cardiometabolic Phase 2 readout for VTX3232 is now public and positive. The science on this asset is largely de-risked. The remaining clinical update this year is the recurrent pericarditis readout for VTX2735. If successful, that would establish a second validated program in a commercially meaningful cardiovascular indication. The key shift now is on the business side: Sanofi holds a Right of First Negotiation on VTX3232 (source: SEC Form 10-Q / 8-K). With the latest data now available, that negotiation window has effectively opened , which means Sanofi is reviewing the full dataset right now, ahead of the rest of the market. Market cap is still around $600M. Any visibility on partnering or commercial strategy can materially re-rate valuation from here. This is no longer a biology story. It’s now a strategic one.
0 · Reply
userD
userD Oct. 25 at 5:52 PM
$VTYX $VIGL $TRML
0 · Reply
buttermeupalready
buttermeupalready Oct. 25 at 4:36 PM
$VTYX this thing is a gem and going to be one of the shining stars for biotech in 25
0 · Reply
Longroader
Longroader Oct. 25 at 3:36 PM
$VTYX Sanofi bought $VIGL for $470M + $100M CVR for a single P1 Alzheimers'. And $TRML was bought out for $1.4B. ASCVD. Ignore the noise. Stay focused.
0 · Reply
agamemnus
agamemnus Oct. 25 at 1:29 PM
$VTYX clinical efficacy data in recurrent pericarditis likely coming mid-November. That's a pretty rare condition.. 10-20,000 patients in the US. Likely qualifies for orphan drug status. Current best treatment is through IV, branded Arcalyst. $200K a year. Almost $300M in sales in 2024. Because it's such a rare condition, recurrent pericarditis can get approved relatively quickly. Importantly, there's read-through from VTX-3232 to VTX-2735 because both are NLRP3 inhibitors. More tidbits will be coming on Parkinson's front as well. They're planning a phase 2 trial but I think they will likely simply partner it and ... this can solve the cash runway for the entire company.
1 · Reply
NSAR
NSAR Oct. 25 at 11:16 AM
$VTYX nobody like to buy after a 70/% pop but look how low market cap is relative to other biotech which are much further behind and don’t have as extensive of a pipeline. More importantly, the recent phase 2 results!!!!!!! My point is VTYX is way underpriced even after the 70% pop.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 8:05 AM
Enter: $VTYX Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.60 Sell Price: $0.98 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
trading_insight
trading_insight Oct. 25 at 4:52 AM
🧪 $VTYX Insane gap move with big momentum. Price is now consolidating under heavy cluster resistance. 🔹 Support: 6.64 and 6.67 🔹 Resistance: 6.74 and 7.05 🔹 Needs a high volume breakout over 6.75 to ignite another leg up, otherwise might consolidate further
0 · Reply
agamemnus
agamemnus Oct. 25 at 2:26 AM
$VTYX For anyone new ... the recent Phase 2 had about 43-45 patients per arm. There were four arms (175 patients total) and the result was highly statistically significant.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:21 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VTYX Current Share Price: $7.14 Contracts: $VTYX March 20, 2026 $8 Calls Scale in: $2.07- $2.53 Scale out: $3.22-$4.14 Can Easily Capture: 60% ROI Blended DTE: 148 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Sir_Braxton
Sir_Braxton Oct. 25 at 12:14 AM
$VTYX This silly coward ran behind block. You can always count on newbies preserving their echo chamber which is a train that's never late.
1 · Reply
agamemnus
agamemnus Oct. 24 at 11:58 PM
$VTYX another f*cking idiot who is making shit up for fun.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 11:48 PM
Enter: $VTYX NOV 21 2025 $8 CALLS Buy in Price: $0.55 - $0.65 Take Profit: $0.93 Stop Bleeding: $0.48 ROI Potential: 69% https://moneygroup.us/
0 · Reply
FancyMaple
FancyMaple Oct. 24 at 11:35 PM
$VTYX the phase 2 was only 10 patients... No telling if results are clinically meaningful yet, even if they hit stat sig on biomarkers.
1 · Reply
agamemnus
agamemnus Oct. 24 at 10:34 PM
$VTYX idiot. Changes his thesis and then calls people bozos. He is the bozo. Blocked!
0 · Reply
marvinnoah
marvinnoah Oct. 24 at 10:09 PM
$VTYX VTYX - Strong Gap-Up on Catalyst, Watching for Delayed Setup Strong gap-up on solid catalyst! But market remains hostile to breakouts. Watch for delayed-reaction setup next. Key local support 6.20 - 5.40 for any pullback.
1 · Reply
Theflash88
Theflash88 Oct. 24 at 9:31 PM
$VTYX Adding .. down because an offering is expected. Then it will rise back up..
1 · Reply